Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 13/20 | 0.64 |
| ▸ | F10 | P00742 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5214927 | 0.89 | CCR2 (0.59) | CCR2F10LMNAMAPTALDH1A1 | |
| SCHEMBL13015139 | 0.85 | P2RX4 (0.59) | CCR2F10ALDH1A1HPGDGAA | |
| SCHEMBL5221120 | 0.84 | CCR2 (0.61) | CCR2F10LMNAMAPTALDH1A1 | |
| SCHEMBL21465576 | 0.77 | ABCB11 (0.56) | CCR2LMNAMAPTALDH1A1HPGD | |
| SCHEMBL5213680 | 0.76 | CCR2 (0.65) | CCR2F10LMNAMAPTALDH1A1 | |
| SCHEMBL21465479 | 0.76 | ABCB11 (0.67) | CCR2LMNAMAPTALDH1A1CYP1A2 | |
| SCHEMBL6300552 | 0.76 | ABCB11 (0.53) | CCR2MAPTCYP3A4ABCB11KMT2A | |
| SCHEMBL6307042 | 0.76 | CCR2 (0.77) | CCR2LMNAMAPTALDH1A1HPGD | |
| SCHEMBL21465543 | 0.76 | CCR2 (0.57) | CCR2MAPTALDH1A1CYP3A4ABCB11 | |
| SCHEMBL6599738 | 0.76 | CCR2 (1.00) | CCR2LMNAMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1173421-B1 | INDOLE DERIVATIVES AS ANTI-INFLAMMATION AGENTS | ASTRAZENECA AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| US-6953809-B2 | Monocyte chemoattractant protein-1 inhibitor compounds | ZENECA LIMITED (GB) | 2005-10-11 | — | — | US | disclosed |
| US-6833387-B1 | 3-substituted indoles; inhibition of monocyte chemoattractant protein-1 and/or RANTES induced chemotaxis; inflammatory diseases | ASTRAZENECA AB (SE) | 2004-12-21 | — | — | US | disclosed |
| EP-1003504-B1 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2003-07-02 | — | — | EP | disclosed |
| US-20030119830-A1 | Monocyte chemoattractant protein-1 inhibitor compounds | ZENECA LIMITED | 2003-06-26 | — | — | US | disclosed |
| US-6441004-B1 | INDOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | ZENECA LIMITED (GB) | 2002-08-27 | — | — | US | disclosed |
| EP-1173421-A2 | INDOLE DERIVATIVES AS ANTI-INFLAMMATION AGENTS | AstraZeneca AB (SE) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000046199-A2 | INDOLE DERIVATIVES AS ANTI-INFLAMMATION AGENTS | ASTRAZENECA AB (SE) | 2000-08-10 | — | — | WO | disclosed |
| EP-1003504-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | AstraZeneca UK Limited (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999007351-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | ZENECA LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119830-A1 | Monocyte chemoattractant protein-1 inhibitor compounds | CCL2, CCL11, CCR1 | CCR2 4/4885F10 485/4885LMNA 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.